Evidence map›Paper›PMID 41842907›Full record

ArticleJournal of molecular cell biology2026

Zbtb38 transcriptionally activates XIAP to regulate apoptosis in development and cancer.

Toshiaki Shigeoka, Hiroyuki Nagaoka, Nunuk Aries Nurulita, Shogo Tada, Yasumasa Bessho, Yasumasa Ishida, Eishou Matsuda

Abstract read
In one paragraph

Article in Journal of molecular cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Toshiaki ShigeokaFunctional Genomics and Medicine, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Hiroyuki NagaokaFunctional Genomics and Medicine, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Nunuk Aries NurulitaFaculty of Pharmacy, University of Muhammadiyah Purwokerto, Jalan Raya Dukuhwaluh PO BOX 202, Purwokerto 53052, Indonesia.
Shogo TadaFunctional Genomics and Medicine, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Yasumasa BesshoGene Regulation Research, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Yasumasa IshidaFunctional Genomics and Medicine, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.ORCID 0009-0007-1431-1941
Eishou MatsudaFunctional Genomics and Medicine, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.

Funding

Japan Society for the Promotion of Science 16K08587Japan Society for the Promotion of Science 22K06883
6 · The paper itself

Abstract

The X-linked inhibitor of apoptosis protein (XIAP) is a key suppressor of apoptosis, crucial for cellular differentiation, embryogenesis, and cancer progression. However, its upstream regulatory mechanisms remain poorly understood. Here, we demonstrate that the zinc finger transcription factor Zbtb38, a negative regulator of apoptosis, modulates XIAP expression in both loss- and gain-of-function experiments, irrespective of p53 expression. Notably, XIAP overexpression rescues the apoptosis induced by Zbtb38 knockdown, indicating that Zbtb38-associated apoptosis is at least partially XIAP-dependent. Mechanistically, Zbtb38 binds to E-box motifs within upstream regulatory regions of XIAP and activates its transcription. During embryonic stem cell differentiation and embryogenesis, Zbtb38 depletion increases apoptosis and reduces XIAP and Bcl-2 expression, underscoring their functional relevance in these processes. Analysis of human tumor datasets reveals a strong positive correlation between ZBTB38 and XIAP expression, with elevated ZBTB38 levels associated with high-grade malignancies. Furthermore, Zbtb38 knockdown induces apoptosis in cancer cells with reduced XIAP expression, regardless of p53 expression. Collectively, these findings uncover a novel Zbtb38-XIAP axis that regulates apoptosis during cellular differentiation, development, and oncogenesis and highlight its therapeutic potential in XIAP-driven and p53-deficient tumors.

Indexed as

ApoptosisNeoplasmsRepressor ProteinsX-Linked Inhibitor of Apoptosis ProteinAnimalsCell DifferentiationCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceTranscriptional ActivationTumor Suppressor Protein p53Repressor ProteinsTumor Suppressor Protein p53XIAP protein, humanX-Linked Inhibitor of Apoptosis ProteinapoptosisBcl-2cancerembryonic developmentembryonic stem cell differentiationXIAP

Identifiers

PMID41842907
PMCPMC13344426

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.